BD acquisition expands treatment for chronic venous disease

Listen to this article

Expanding the range of products it can offer to physicians treating venous disease, and marking its entrance into the area, BD said Dec. 2 it is acquiring Venclose Inc.

Founded in 2014, the company’s Venclose System is used for the treatment of chronic venous insufficiency (CVI), a disease that comes about from malfunctioning valves, according to Franklin Lakes-based BD, and can lead to varicose veins.

“We’re committed to setting a new standard of excellence for people living with venous disease, and that starts with providing physicians with innovative technologies,” said Paddy O’Brien, worldwide president of peripheral intervention for BD. “The Venclose RF Ablation System strategically complements our category-leading portfolio of venous disease technologies and aligns with our focus on innovations that provide transformative solutions to improve outcomes for chronic disease and enable the transition into new care settings.”

CVI affects up to 40% of women and 17% of men in the United States, BD said in a deal announcement, describing the target as a leader in its treatment.

As opposed to treating with lasers, Radio Frequency ablation technology used by Venclose – the predominant treatment for CVI – can reduce post-operative pain and bruising.

The Venclose System features two heating lengths – 2.5 centimeters and 10 centimeters – in one 6 FR sized catheter. The dual heating lengths allow ablation of both short and long vein segments with the same catheter.

BD said physicians are afforded additional operational benefits from the tool, including 30% more heating length over the longest leading competitive RF ablation catheter, allowing physicians to efficiently ablate more vein during heating cycles, for fewer ablations overall during in-vein treatment.

The system also helps to ensure a patient-centric experience, with a touchscreen display that provides real-time procedure data, and audible tones to signal thermal delivery, which allow physicians to focus more on the patient.

It is available across the U.S. and in areas of Europe.

Terms of the deal were not disclosed. BD said that it is expected to be immaterial to its 2022 financial results.